Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cells are a novel immunotherapy available for patients with refractory/relapsed non-Hodgkin lymphoma. In this indication, clinical trials have demonstrated that CAR T-cells achieve high rates of response, complete response, and long-term response (up to 80%, 60%, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vercellino, Laetitia, de Jong, Dorine, di Blasi, Roberta, Kanoun, Salim, Reshef, Ran, Schwartz, Lawrence H., Dercle, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195284/
https://www.ncbi.nlm.nih.gov/pubmed/34123825
http://dx.doi.org/10.3389/fonc.2021.664688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195284/
https://www.ncbi.nlm.nih.gov/pubmed/34123825
http://dx.doi.org/10.3389/fonc.2021.664688

Ejemplares similares